Published in Cancer Weekly, August 17th, 2004
DMAG is a second-generation Hsp90 inhibitor that is highly potent and water soluble and has good oral bioavailability.
Kosan's first-generation Hsp90 inhibitor includes an original drug substance 17-AAG in a DMSO and egg lecithin vehicle and a new formulation, KOS-953, both of which are being evaluated in the clinic.
The DMAG clinical trial is sponsored by the National Cancer Institute (NCI) under a Cooperative Research and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.